Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 8/20 | 0.42 |
| ▸ | CES1 | P23141 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279130 | 1.00 | MAPT (0.59) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL6563475 | 0.85 | KDM4E (0.61) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL18920183 | 0.81 | MAPT (0.58) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL190077 | 0.81 | MAPT (0.43) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL190574 | 0.81 | MAPT (0.43) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL15262342 | 0.78 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL68742 | 0.78 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL15261386 | 0.78 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL17338126 | 0.78 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL15261467 | 0.78 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918618-B2 | Methods of reducing microbial contamination | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-02-16 | — | — | US | disclosed |
| EP-2497459-B1 | Methods of reducing microbial contamination | 3M INNOVATIVE PROPERTIES CO (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3025704-B1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | 3M INNOVATIVE PROPERTIES CO (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180207122-A1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-07-26 | — | — | US | disclosed |
| EP-3025704-A1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | 3M Innovative Properties Company (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150094368-A1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-04-02 | — | — | US | disclosed |
| EP-1858482-B1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | 3M INNOVATIVE PROPERTIES CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8476319-B2 | Methods of treating ear infections | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2497460-A1 | Methods of reducing microbial contamination | 3M Innovative Properties Co. (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2497459-A1 | Methods of reducing microbial contamination | 3M Innovative Properties Co. (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20090226541-A1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090005339-A1 | Methods of Treating Ear Infections | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1858506-A2 | METHODS OF TREATING EAR INFECTIONS | 3M Innovative Properties Company (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1858482-A2 | METHODS OF REDUCING MICROBIAL CONTAMINATION | 3M Innovative Properties Company (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006099359-A2 | METHODS OF REDUCING MICROBIAL CONTAMINATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099325-A2 | METHODS OF TREATING EAR INFECTIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918618-B2 | Methods of reducing microbial contamination | LPO, CAT, UNG | MAPT 3852/4885FAAH 1903/4885CES1 2880/4885 |
| US-20150094368-A1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | LPO, CAT, UNG | MAPT 3852/4885FAAH 1903/4885CES1 2880/4885 |
| US-20090226541-A1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | LPO, CAT, UNG | MAPT 3852/4885FAAH 1903/4885CES1 2880/4885 |
| US-20090005339-A1 | Methods of Treating Ear Infections | OTC, COXFA4L2, MYOC | MAPT 4417/4885FAAH 831/4885CES1 2033/4885 |
| US-20180207122-A1 | METHODS OF REDUCING MICROBIAL CONTAMINATION | LPO, CAT, UNG | MAPT 3852/4885FAAH 1903/4885CES1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.